Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.

ABSTRACT: Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5-10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m² cumulative dose of DOX from four cycles of t

SUBMITTER: Yu LR 

PROVIDER: S-EPMC5813873 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature